Abstract
BackgroundThe molecular targets of the vast majority of autoantibodies in systemic lupus erythematosus (SLE) are unknown. Multiple recent failures of new therapies in SLE clinical trials demonstrate the need for...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
